TBI为主的不含ATG的清髓性预处理方案在非血缘脐血移植治疗成人恶性血液病中的应用
Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies
摘要
目的 分析采用全身照射(TBI)为主的不含抗胸腺细胞球蛋白(ATG)的清髓性预处理方案进行非血缘脐血移植(UCBT)治疗成人恶性血液病的安全性和疗效.方法 2006年9月至2011年5月,单中心采用不含ATG由TBI、阿糖胞苷(Ara-c)、环磷酰胺(CY)组成的清髓性预处理方案进行UCBT治疗40例成人恶性血液病患者.患者平均年龄(23±6)岁,平均体重(58±9) kg.40例患者中高危难治患者35例(87.5%),进展期进行移植患者15例(37.5%).单份脐血移植23例,双份脐血移植17例.75.0% (30/40)患者存在HLA 1 ~2个位点不合.移植物抗宿主病(GVHD)预防采用环孢素A联合霉酚酸酯方案.结果 受者输入脐血总有核细胞平均数为(4.1±1.1)×107/kg,CD34+细胞平均数为(2.4±1.0)×105/kg.40例患者全部获得植入,植入率100%.中性粒细胞绝对值≥0.5×109/L的平均时间为(20±5)d,血小板≥20×109/L的平均时间为(38±12)d.40例中23例(57.5%)发生急性GVHD,其中Ⅲ~Ⅳ度4例(10.0%).可评估的35例患者中8例(22.9%)发生慢性GVHD,均为局限型.12.5% (5/40)患者复发.存活患者中位随访时间19.8(4.6 ~55.0)个月.100 d和1年移植相关病死率分别为15.0%、35.0%.主要死亡原因为严重肺部感染和重度急性GVHD.2年无病生存率和总生存率均为58.8%.疾病进展期与缓解期进行移植的患者2年累计生存率分别为48.6%和63.8%,差异无统计学意义(x2=0.304,P =0.582).结论 采用TBI/Ara-c/CY预处理方案行成人UCBT耐受性好,全部患者均获得稳定植入,降低早期移植相关死亡.该方案用于高危、难治和进展期患者移植后复发率较低,慢性GVHD发生率低并均为局限型,获得较理想的生存率.
Objective To retrospectively analyze the curative efficacy of umbilical cord blood transplantation (UCBT) with improved myeloablative conditioning regimen (total body irradiation (TBI)/cytosine arabinoside ( Ara-c)/cyclophosphamide (CY) without antithymocyte globulin ( ATG ) ) in adult patients with hematological malignancies. Methods Forty consecutive adult patients with hematological malignancies received improved myeloablative unrelated CBT at a single center from September 2006 to May 2011.Their average age was ( 23 ± 6 ) years and the average weight ( 58 ± 9 ) kg.Thirty-five ( 87.5% )patients were high-risk and 15 (37.5% )at the advanced disease status at pre-transplantation.They received 1 ( n =23 ) or 2 ( n =17 ) cord blood units.Seventy-five percent of them were transplanted with 1/2- human leukocyte antigen mismatched unit.The conditioning regimen consisted of 12 Gy TBI,granulocyte colonystimulating factor (G-CSF) plus Ara-c and CY without ATG. All patients received a combination of cyclosporine (CsA) and mycophenolate mofetil (MMF) for the prophylaxis of graft-versus-host disease (GVHD).Results For the entire group of patients,the average cell doses infused were (4.1 ± 1.1 ) × 107 total nucleated cells/kg and ( 2.4 ± 1.0) × 105 CD34+ cells/kg.All patients acquired engraftment with an implantation rate of 100%.The average time of absolute neutrophil count (ANC) ≥ 0.5 × 109/L was (20 ±5) days and the average time of platelet ≥20 × 109/L was(38 ± 12)days.Acute GVHD occurred in 23 patients( 57.5% ) and 4 ( 10.0% ) were of grade Ⅲ - Ⅳ.Chronic GVHD occurred in 22.9% ( 8/35 ) evaluable patients.Relapse occurred in 12.5% (5/40) patients.During a median follow-up period of 19.8 ( range 4.6 - 55.0 ) months,the transplantation-related mortality was 15.0% (6/40) within 100 days and 35.0% (14/40) within 1 year.The main causes of mortality were pneumonia and severe acute GVHD.Two-year overall survival (05) or disease-free survival was 58.8% and 58.8%,respectively.Two-year OS for patients with advanced or complete remission disease was 48.6% and 63.8%,respectively.Conclnsions The TBI/Ara-c/CY myeloablative conditioning regimen is well-tolerated and capable of establishing sustained donor cell engraftment and decreasing the risks of transplant-related death in adults with hematologic malignancies.For the high-risk and advanced patients,it may reduce the occurrences of relapse and chronic GVHD.
Author:
SUN Zi-min
LIU Hui-lan
GENG Liang-quan
ZHOU Chen-yang
WANG Xing-bing
DING Kai-yang
TONG Juan
ZHU Wei-bo
LIU Xin
WANG Zu-yi
作者单位:
安徽医科大学附属安徽省立医院血液科,合肥,230001
年,卷(期):
2012, 92(24)
分类号:
R4
机标分类号:
R735.2
R457.7
R556.5
在线出版日期:
2012年10月24日
基金项目:
11010402164:安徽省科技攻关计划(十二五)2010A005:安徽省卫生厅医学科研重点项目,